COMMUNIQUÉS West-GlobeNewswire

Seer to Participate in Upcoming November Investor Conferences
29/10/2025
REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced company management will be participating in the [...]
Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025
29/10/2025
REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
29/10/2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , announced today that its third quarter 2025 financial results will be released before the market opens [...]
Prenetics CEO Danny Yeung Publishes "The Dual-Engine Revolution" Manifesto: A Blueprint for the Future of Health + Wealth
29/10/2025
Comprehensive Document Reveals Strategic Vision Behind Company's Unprecedented Growth and Bitcoin Treasury Strategy IM8, the Fastest-Growing Supplement Brand in Industry History, Reaching Reaches $100M ARR in 11 Months [...]
OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results
29/10/2025
Conference call begins at 4:30 p.m. Eastern time today MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months [...]
AVITA Medical to Announce Third Quarter 2025 Financial Results
29/10/2025
VALENCIA, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, [...]
Emergent BioSolutions Reports Third Quarter 2025 Financial Results
29/10/2025
Third Quarter 2025 Total Revenues of $231.1 million, above the high end of Q3 guidance by $21.0 million Third Quarter 2025 Net Income of $51.2 million and Net Income Margin of 22% Third Quarter 2025 Gross Margin % of 54 [...]
Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
29/10/2025
Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is generally safe and [...]
STERIS Announces Dividend of $0.63 per share
29/10/2025
DUBLIN, IRELAND, Oct. 29, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on [...]
Cytek® Biosciences Deepens Commitment to Expanding Access to Flow Cytometry
29/10/2025
Supports ISAC in Mission to Extend Flow Cytometry Reach Worldwide; Unveils Programs Offering Instrument Award and Research Grants FREMONT, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amid the reduction of various [...]
Vaxil Announces Non-Brokered Private Placement
29/10/2025
Not for distribution by US newswire or in United States NESS-ZIONA, ISRAEL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“ Vaxil ” or the “ Company ”) (TSX VENTURE: VXL), is pleased to announce that the Company [...]
Aja Health and Wellness Inc. Provides Update on Delay in Filing Financial Statements
29/10/2025
Not for dissemination in the United States of America VANCOUVER, British Columbia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Aja Health and Wellness Inc. ("Aja" or the "Company") (TSXV:Aja) announces that it is getting closer [...]
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
29/10/2025
NovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for wet AMD, VIS-101, leveraging Everest Medicines’ strong clinical and [...]
DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq
29/10/2025
Châtillon, France, 29 octobre 2025 DBV Technologies annonce un placement d’ADS pour un montant d’environ 30 millions de Dollars US dans le cadre de son programme At-The-Market (ATM) sur le Nasdaq DBV Technologies (la « [...]
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
29/10/2025
Châtillon, France, October 29, 2025 DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq [...]
Curia publie son rapport ESG (environnement, social et gouvernance) 2024
29/10/2025
ALBANY, New York, 29 oct. 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), l’une des principales organisations de recherche, de développement et de fabrication sous contrat, a annoncé aujourd’hui la publication de [...]
CORRECTION – Solana Company Announces Updated SOL Holdings and Industry Leading Staking Yield
29/10/2025
NEWTOWN, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Wednesday, October 29th by Solana Company (NASDAQ: HSDT), please note that in the first sentence of the third paragraph, the [...]
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
29/10/2025
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 29 octobre 2025 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui [...]
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
29/10/2025
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 29 octobre 2025 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui [...]

Pages